Everything on this page was good news. For somebody else.
An election surprised, a vaccine trial hit every endpoint, a logistics company bought a rival at a 29% premium, and an investor put $37.5 billion on a division nobody can buy yet. Four traders were standing on the far side of all of it.
Read the damage →